Bifogade filer
The last day of trading with the warrants of series TO10B in iZafe Group AB is today, October 7, 2022
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Today, October 7, 2022, is the last day of trading with the warrants of series TO10B in iZafe Group AB (“iZafe” or “the Company”). The subscription period for the warrants of series TO10B runs up until October 11, 2022. Each warrant of series TO10B gives the owner the right to subscribe for one (1) new share of series B in iZafe. The exercise price for the warrants of series TO10B is SEK 0.26 per share of series B.
If all the warrants of series TO10B are exercised, the Company will receive approximately SEK 9.2 million before issuing costs. In order to prevent the warrants expiring without value, the holder must actively subscribe for new shares, no later than October 11, 2022. Alternatively, the holder may sell the warrants, no later than today, October 7, 2022. Please be aware that certain nominees may close their subscriptions earlier than October 11, 2022. Complete terms and conditions for the warrants are available on the Company’s website, www.izafegroup.com.
Summarized terms for the warrants of series TO10B:
Exercise period: September 27, 2022 – October 11, 2022.
Exercise price: SEK 0.26 per share of series B.
Issue size: 35,435,674 warrants of series TO10B, which entitles to subscription of 35,435,674 shares of series B. If all the warrants are exercised, The Company will receive approximately SEK 9.2 million before issuing costs.
Last day for trading warrants of series TO10B: October 7, 2022.
Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 7,087,134.80, from SEK 14,174,861.60 to SEK 21,261,996.40. If all warrants are exercised the number of shares will increase with 35,435,674 shares of series B, in total the number of shares in the Company will increase from 70,874,308 shares to 106,309,982 shares (600,000 shares of series A and 105,709,982 shares of series B). The dilution at full exercise of all warrants amounts to approximately 33.33 percent of the number of shares and 31.72 percent of the votes in the Company.
Note that the warrants of series TO10B that are not exercised at the latest October 11, 2022, or sold at the latest October 7, 2022, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.
Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO10B.